ArticleCureus2024
Serum Brain-Derived Neurotrophic Factor: An Emerging Marker for Diabetic Retinopathy.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Neuroprotection in Early Diabetic Retinal Disease Using Eyedrop Delivery.International journal of molecular sciences · 2026Review
- Identification of serum protein biomarkers in individuals with Niemann-Pick disease, type C1.Research square · 2026Article
- Neuroprotective potential of a plant-based intervention in diabetic neuropathy: Biochemical and behavioral insights from a streptozotocin-induced rat model.World journal of diabetes · 2026Article
- Identification of serum protein biomarkers in individuals with Niemann-Pick disease, type C1.medRxiv : the preprint server for health sciences · 2026Article
- Exerkines in diabetic retinopathy: from mechanisms to therapeutic prospects.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetes mellitus (DM) is a global disease that is strongly associated with both microvascular and macrovascular complications. A significant proportion of individuals with diabetes develop diabetic retinopathy (DR), a microvascular complication that can lead to blindness, particularly in working-age adults. Diabetes adversely affects the entire neurosensory retina, with accelerated neuronal apoptosis and activation or altered metabolism of neuroretinal supporting cells. These findings suggest that DR could be a sensory neuropathy that affects the retinal parenchyma, similar to peripheral diabetic neuropathy. Neurotrophins have been implicated in the progression of DR. This study was done to determine the association of serum brain-derived neurotrophic factor (BDNF) levels with DR in type 2 diabetic patients in a tertiary care hospital in North India.
methodsA hospital-based case-control study was done. The case group included diabetic patients with retinopathy (n=44) and the control group included diabetic patients without retinopathy (n=44). Serum BDNF levels were estimated by enzyme-linked immunosorbent assay (ELISA). Statistical analysis was carried out using GraphPad Prism software (Dotmatics, Boston, USA).
resultsThe mean serum BDNF in the control and case groups was 2753 ± 465 pg/ml and 1598 ± 483 pg/ml, respectively. The difference between the two groups was statistically significant as per the Mann-Whitney U test (U=64, p<0.0001). Logistic regression analysis showed that BDNF is a good predictor for DR after multivariate regression.
conclusionsPatients with DR were found to have lower serum BDNF levels compared to those without retinopathy. BDNF may serve as an early predictor for DR. Due to its role in neuronal health and metabolism, increasing BDNF levels could offer a therapeutic approach to managing diabetes-related complications. However, further research is needed to confirm the effectiveness of BDNF in slowing or preventing the progression of DR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.